Patient characteristics
12 patients with previously treated MUM were enrolled from July 2019 to January 2022. Three patients were treated at each DL (Patient characteristics.* Includes ipilimumab/nivolumab, pembrolizumab, nivolumab.Overview of demographics and prior therapies for the 12 patients enrolled in the trial.